Chronic Lymphocytic Leukemia Treatment Advances: Impact on Patient Care and Outcomes
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia, primarily affecting older adults. Recent developments in CLL treatment have shifted from traditional chemotherapy to targeted therapies, significantly altering patient care. Historically, CLL treatment involved chemotherapy regimens like fludarabine, cyclophosphamide, and rituximab, which were associated with high toxicity and limited benefits, especially for older patients. However, the introduction of targeted therapies, such as Bruton’s tyrosine kinase (BTK) inhibitors, has transformed the treatment landscape. These inhibitors, including ibrutinib, acalabrutinib, and zanubrutinib, block proteins essential for CLL cell survival, offering prolonged disease control with fewer side effects. Additionally, fixed-duration therapies combining venetoclax with other agents have emerged, providing deep remissions and allowing patients to discontinue treatment after a year if remission is achieved. This approach minimizes long-term medication u... 
